Trial NCT04366908
Publication Entrenas Castillo M, J Steroid Biochem Mo (2020) (published paper)
Funding: Public/non profit (Maimónides Biomedical Research Institute of Córdoba)
Conflict of interest: *
Methods | |
RCT Blinding: Unblinded | |
Location :
Single center / Spain Follow-up duration (days): 28 | |
Inclusion criteria |
|
Exclusion criteria |
|
Interventions | |
Treatment
Calcifediol 532 mcg orally on day 1, followed by 266 mcg on days 3 and 7 then weekly until discharge or ICU admission |
|
Control
Standard care | |
Participants | |
Randomized participants : Calcifediol=50 Standard care=26 | |
Characteristics of participants N= 76 Mean age : NR 45 males Severity : Mild: n=0 / Moderate: n=* / Severe: n=* Critical: n=0 Number of vaccinated participants: NR | |
Primary outcome | |
In the register Proportion of subjects who enter the ICU; Proportion of subjects who die (Time Frame: At day 28) | |
In the report Rate of ICU admission and death | |
Documents available |
Protocol NR Statistical plan NR Data-sharing willing stated in the publication: Yes |
Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
Some concerns |
General comment | In addition to the published report of the pilot study (journal pre-proof), the study registry was used in data extraction. There is no change from the trial registration in the intervention and control treatments. Pre-specified secondary outcomes included in the registry were not reported. Serum 25OHD concentrations at baseline or during treatment are not available. There were 2 deaths (control arm) out of 80 participants. It was not possible to find the exact timepoint for discharge, though not extracted. |